Diving deeper into inherited retinal disorders, Novartis gobbles up another bite-sized optogenetics biotech
Right about a year ago, a Novartis team led by Jay Bradner and Cynthia Grosskreutz at NIBR swooped in to scoop up a Cambridge, MA-based opthalmology gene therapy company called Vedere. Their focus was on a specific market niche: inherited retinal dystrophies that include a wide range of genetic retinal disorders marked by the loss of photoreceptor cells and progressive vision loss.
But that was just the first deal that whet their appetite.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 119,800+ biopharma pros reading Endpoints daily — and it's free.